The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course
Do not increase your dose faster than recommended
Although Semaglutide GLP-1 is an effective tool for achieving weight loss, if you want to continue to enjoy the results after stopping the medication, you will need to be extra diligent about sticking to healthy habits
However, if the patient experiences any serious side effects, the dose of the drug should be reduced or discontinued
Patients often choose semaglutide because: Semaglutide is commonly used as part of our medically supervised program that includes lifestyle guidance, nutrition counseling, and ongoing monitoring
